Introduction
Growth hormone deficiency resulting in short stature may occur in the absence of an obvious structural lesion in the pituitary-hypothalamic area as an isolated defect or as part of the syndrome of idiopathic hypopituitarism. Both may occur sporadically or in families (Goodman, Grumbach and Kaplan, 1968) . Studies of families suggest autosomal recessive inheritance (Trygstad and Seip, 1964) . Until recently it was only possible to guess that trophic hormone deficiency existed by extrapolating from tests of pituitary function but with the availability of gonadotrophin releasing hormone (LH/FSH-RH) and thyrotrophin releasing hormone (TRH) and serum assays for pituitary hormones defective pituitary reserve can be documented. Job et al. (1972) showed a failure of thyrotrophin (TSH) to rise in response to TRH in a dwarfed child who had growth hormone deficiency and Chaussain et al. (1972) have tested gonadotrophin reserve in similar children. In their series of five patients with growth hormone deficiency, one female had a normal gonadotrophin reserve and four males had impaired or absent reserves.
Radiological studies have shown that the pituitary fossa size of one-third of patients with idiopathic hypopituitarism is abnormally small, the volume being more than two standard deviations below the age and height related means of the control group (Underwood et al., 1973) . This is in keeping with the findings of Goodman et al. (1968) and our own experience.
The nitrogen retaining and hypercalcuric action of growth hormone can be used to test growth hormone responsiveness in susceptible subjects. Though there are conflicting reports as to prognostic use as far as future growth is concerned (Melvin et al., 1967; Clayton, Tanner and Vince, 1971 ) these tests are of value in demonstrating target organ sensitivity to an administered preparation of human growth hormone.
We report on three sisters, of consanguinous healthy parents, with multiple trophic hormone deficiencies presenting as short stature. Our data includes assessment of their pituitary function, their acute response to human growth hormone and we also describe rather unusual radiological features of the sella turcica.
Case history
A, S and K, three sisters aged 10 years 4 months, 12 years 9 months and 17 years 6 months respectively were referred for investigation and treatment of short stature. The pregnancies had been uneventful and their sizes, though not measured, were believed to be normal at birth. At the age of 2-3 years, growth retardation was noted in each although all have continued to grow slowly. Intelligence is judged as normal for their chronological age. There has been no sexual development in any.
The parents are first cousins: their heights are normal and the mid-parental height is 'average' by British standards. There is no family history of short stature and seven other siblings are said to be of normal height.
Examination Figure 1 shows their general appearance and Fig. 2 their heights in relation to the 3rd, 50th and 97th centiles for British children (Tanner, 1958 (Tanner, 1958) . adult proportions and their head circumferences were normal in relation to their heights. They had soft skin, immature facies and were all prepubertal. Clinically, they were euthyroid and euadrenal. All three had blue sclerae and in S this was quite conspicuous.
Investigations General
Routine urinalysis, blood urea, creatinine, calcium, phosphate, electrolytes and fasting blood sugars were within normal limits. All of them were slightly anaemic and blood films were suggestive of thalassaemia trait: this was tested for in the eldest and Pthalassaemia trait confirmed. All had normal electrocardiograms. Chromosome studies showed normal karyotypes and faecal fat excretion was normal in all three.
Radiology
Their bone ages were 2-5, 3-5 and 4 years and their dental ages 7, 10 and 10 years respectively. Skull Xrays in A and K showed a slightly ballooned sella, which also appeared large in relation to the size of the skull (Fig. 3) . In these two, the lateral area was more than 2 standard deviations above the mean for skeletal age and height. This abnormality was still evident when pituitary volume was measured and compared with the normal range for their skeletal age (Fisher and Di Chiro, 1964) . S had a normallooking sella (Fig. 4) and its lateral area was close to the mean for her skeletal age. Figure 5 shows the (Silverman, 1957) . lateral sella areas in all three children plotted against skeletal and chronological age and compared with the sella areas found in normal children (Silverman, 1957) .
Endocrine (a) Pituitary function (Table 1) . A combined test of anterior pituitary function was carried out as described by Harsoulis et al. (1973) using insulin (0-25 u/kg given i.v.), LH/FSH-RH (100 jig i.v.) and TRH (200 ,ug i.v.) . Cortisol was measured by the competitive protein binding method of Beardwell, Burke and Cope (1968) . Growth hormone, luteinizing hormone (LH), follicle stimulating hormone (FSH), TSH and prolactin were assayed against the following standards: WHO first IRP for growth hormone, MRC 69/104 for LH and FSH, MRC 68/38 for TSH and Friesen 72-4-9 for prolactin.
The basal and stimulation results are shown in (c) Acute metabolic response to human growth hormone. The patients were studied for 4 days before and for 6 days on intramuscular human growth hormone (Crescormon: Kabi) using a dose of 10 iu daily in A and S and 12 iu daily in K. Blood urea, urine urea and urine calcium levels were followed on a constant protein intake and a calcium intake of 2 mEq/kg/day. The mean changes that occurred during the treatment period are shown in Table 3 . These changes were compared with the changes found by Melvin et al. (1967) in hypopituitary subjects given 10 iu of human growth hormone intramuscularly daily for 3 days.
Discussion
It has been suggested that in idiopathic hypopituitarism, trophic hormone deficiencies are acquired progressively (Goodman et al., 1968 show an acute metabolic response to this hormone, it is proposed to treat them with Crescormon on a twice weekly basis. K will also receive thyroxine replacement therapy.
